Constantinos Televantos, Phillip J Monaghan, Maria Michaelidou, Lillian Ruiheng Chen, Mohammed Ahmed, Jan Hoong Ho, Shaishav Dhage, Claire Higham, Brian Keevil, Safwaan Adam
{"title":"Diagnostic Accuracy Study of Morning Salivary Cortisone for Screening Adrenal Insufficiency in a Real-World Cohort.","authors":"Constantinos Televantos, Phillip J Monaghan, Maria Michaelidou, Lillian Ruiheng Chen, Mohammed Ahmed, Jan Hoong Ho, Shaishav Dhage, Claire Higham, Brian Keevil, Safwaan Adam","doi":"10.1210/clinem/dgag401","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Morning serum cortisol is used to screen for adrenal insufficiency, but requires venepuncture, early morning clinic attendance, and may be affected by altered corticosteroid-binding globulin (CBG) levels. Salivary cortisone is a non-invasive, home-based alternative.</p><p><strong>Objective: </strong>To assess the diagnostic accuracy of morning salivary cortisone for screening adrenal insufficiency and establish clinically relevant thresholds.</p><p><strong>Design: </strong>Retrospective cross-sectional diagnostic accuracy study (2017 to 2024).</p><p><strong>Setting: </strong>Single tertiary oncology and endocrinology center in the United Kingdom.</p><p><strong>Participants: </strong>Consecutive patients undergoing adrenocorticotropin hormone (ACTH) stimulation test for suspected adrenal insufficiency.</p><p><strong>Intervention: </strong>Salivary sampling for cortisone and cortisol.</p><p><strong>Main outcome measures: </strong>Sensitivity and specificity of baseline salivary cortisone.</p><p><strong>Results: </strong>A total of 517 ACTH stimulation tests in 449 participants were included; adrenal insufficiency was confirmed in 104 tests (20.1%). Baseline salivary cortisone accurately predicted adrenal insufficiency (area under the receiver operating characteristic curve [AUC] 0.93, 95% CI [0.91-0.95]), similar to serum cortisol (0.93, 0.90-0.95; p = 0.67) and superior to salivary cortisol (0.87, 0.82-0.91; p = 0.00063). A baseline salivary cortisone rule-out threshold ≥703 ng/dL (19.5 nmol/L) (sensitivity 0.97 [95% CI 0.92-0.99]; specificity 0.59 [0.54-0.63]) and a rule-in threshold <180 ng/dL (5.0 nmol/L) (sensitivity 0.58 [0.48-0.67]; specificity 0.97 [0.95-0.98]) provided the highest net benefit. An intermediate threshold <389 ng/dL (10.8 nmol/L) (sensitivity 0.83 [0.74-0.89]; specificity 0.87 [0.83-0.90]) identified patients for whom glucocorticoid cover should be considered while awaiting confirmatory testing.</p><p><strong>Conclusion: </strong>Baseline morning salivary cortisone performs at least as well as serum cortisol for adrenal insufficiency screening.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of clinical endocrinology and metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/clinem/dgag401","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Context: Morning serum cortisol is used to screen for adrenal insufficiency, but requires venepuncture, early morning clinic attendance, and may be affected by altered corticosteroid-binding globulin (CBG) levels. Salivary cortisone is a non-invasive, home-based alternative.
Objective: To assess the diagnostic accuracy of morning salivary cortisone for screening adrenal insufficiency and establish clinically relevant thresholds.
Design: Retrospective cross-sectional diagnostic accuracy study (2017 to 2024).
Setting: Single tertiary oncology and endocrinology center in the United Kingdom.
Participants: Consecutive patients undergoing adrenocorticotropin hormone (ACTH) stimulation test for suspected adrenal insufficiency.
Intervention: Salivary sampling for cortisone and cortisol.
Main outcome measures: Sensitivity and specificity of baseline salivary cortisone.
Results: A total of 517 ACTH stimulation tests in 449 participants were included; adrenal insufficiency was confirmed in 104 tests (20.1%). Baseline salivary cortisone accurately predicted adrenal insufficiency (area under the receiver operating characteristic curve [AUC] 0.93, 95% CI [0.91-0.95]), similar to serum cortisol (0.93, 0.90-0.95; p = 0.67) and superior to salivary cortisol (0.87, 0.82-0.91; p = 0.00063). A baseline salivary cortisone rule-out threshold ≥703 ng/dL (19.5 nmol/L) (sensitivity 0.97 [95% CI 0.92-0.99]; specificity 0.59 [0.54-0.63]) and a rule-in threshold <180 ng/dL (5.0 nmol/L) (sensitivity 0.58 [0.48-0.67]; specificity 0.97 [0.95-0.98]) provided the highest net benefit. An intermediate threshold <389 ng/dL (10.8 nmol/L) (sensitivity 0.83 [0.74-0.89]; specificity 0.87 [0.83-0.90]) identified patients for whom glucocorticoid cover should be considered while awaiting confirmatory testing.
Conclusion: Baseline morning salivary cortisone performs at least as well as serum cortisol for adrenal insufficiency screening.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
